Last reviewed · How we verify

AG-120 — Competitive Intelligence Brief

AG-120 (AG-120) competitive landscape: 1 comparator, recent regulatory actions, upcoming PDUFA, patent timeline. Class: IDH1 inhibitor. Area: Oncology.

phase 3 IDH1 inhibitor IDH1 (isocitrate dehydrogenase 1) Oncology Small molecule Live · refreshed every 30 min

Target snapshot

AG-120 (AG-120) — Institut de Recherches Internationales Servier. AG-120 is an isocitrate dehydrogenase 1 (IDH1) inhibitor that blocks the production of the oncometabolite 2-hydroxyglutarate in IDH1-mutant cancers.

Comparator set (1 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
AG-120 TARGET AG-120 Institut de Recherches Internationales Servier phase 3 IDH1 inhibitor IDH1 (isocitrate dehydrogenase 1)
Ivosidenib Oral Tablet Ivosidenib Oral Tablet Servier Bio-Innovation LLC phase 3 IDH1 inhibitor IDH1 (isocitrate dehydrogenase 1, mutant)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (IDH1 inhibitor class)

  1. Institut de Recherches Internationales Servier · 1 drug in this class
  2. Servier Bio-Innovation LLC · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). AG-120 — Competitive Intelligence Brief. https://druglandscape.com/ci/ag-120. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators: